# A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

> **NCT05152472** · PHASE2 · RECRUITING · sponsor: **Centre Leon Berard** · enrollment: 110 (estimated)

## Conditions studied

- Unresectable Gastrointestinal Stromal Tumor (GIST)
- Locally Advanced Gastrointestinal Stromal Tumor (GIST)
- Metastatic Gastrointestinal Stromal Tumor

## Interventions

- **DRUG:** Atezolizumab 1200 mg
- **DRUG:** Imatinib 400 MG

## Key facts

- **NCT ID:** NCT05152472
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-14
- **Primary completion:** 2027-10
- **Final completion:** 2027-10
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05152472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05152472, "A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05152472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*